Erratum: A budget impact analysis of gene therapy for sickle cell disease: The Medicaid perspective (JAMA Pediatr. (2021) DOI: 10.1001/jamapediatrics.2020.7140)

P. Demartino; M. B. Haag; A. R. Hersh; A. B. Caughey; J. A. Roth

doi:10.1001/jamapediatrics.2021.1438

Erratum: A budget impact analysis of gene therapy for sickle cell disease: The Medicaid perspective (JAMA Pediatr. (2021) DOI: 10.1001/jamapediatrics.2020.7140)

P. Demartino, M. B. Haag, A. R. Hersh, A. B. Caughey, J. A. Roth

Obstetrics and Gynecology

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

Error in the Text: In the Original Investigation titled “A Budget Impact Analysis of Gene Therapy for Sickle Cell Disease: The Medicaid Perspective,” which published online March 22, 2021,1 there was an error in the Introduction section. The third sentence in the fourth paragraph of that section should read: “Agene therapy using the same lentiviral vector received conditional approval from the European Medicines Agency in 2019for the treatment of transfusion-dependent ß-thalassemia.”This article was corrected online.

Original language	English (US)
Pages (from-to)	647
Number of pages	1
Journal	JAMA Pediatrics
Volume	175
Issue number	6
DOIs	https://doi.org/10.1001/jamapediatrics.2021.1438
State	Published - Jun 2021

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health

Access to Document

10.1001/jamapediatrics.2021.1438

Cite this

@article{c6167d592c5a4b5588a13c83eebc7cec,

title = "Erratum: A budget impact analysis of gene therapy for sickle cell disease: The Medicaid perspective (JAMA Pediatr. (2021) DOI: 10.1001/jamapediatrics.2020.7140)",

abstract = "Error in the Text: In the Original Investigation titled “A Budget Impact Analysis of Gene Therapy for Sickle Cell Disease: The Medicaid Perspective,” which published online March 22, 2021,1 there was an error in the Introduction section. The third sentence in the fourth paragraph of that section should read: “Agene therapy using the same lentiviral vector received conditional approval from the European Medicines Agency in 2019for the treatment of transfusion-dependent {\ss}-thalassemia.”This article was corrected online.",

author = "P. Demartino and Haag, {M. B.} and Hersh, {A. R.} and Caughey, {A. B.} and Roth, {J. A.}",

year = "2021",

month = jun,

doi = "10.1001/jamapediatrics.2021.1438",

language = "English (US)",

volume = "175",

pages = "647",

journal = "JAMA Pediatrics",

issn = "2168-6203",

publisher = "American Medical Association",

number = "6",

}

TY - JOUR

T1 - Erratum

T2 - A budget impact analysis of gene therapy for sickle cell disease: The Medicaid perspective (JAMA Pediatr. (2021) DOI: 10.1001/jamapediatrics.2020.7140)

AU - Demartino, P.

AU - Haag, M. B.

AU - Hersh, A. R.

AU - Caughey, A. B.

AU - Roth, J. A.

PY - 2021/6

Y1 - 2021/6

N2 - Error in the Text: In the Original Investigation titled “A Budget Impact Analysis of Gene Therapy for Sickle Cell Disease: The Medicaid Perspective,” which published online March 22, 2021,1 there was an error in the Introduction section. The third sentence in the fourth paragraph of that section should read: “Agene therapy using the same lentiviral vector received conditional approval from the European Medicines Agency in 2019for the treatment of transfusion-dependent ß-thalassemia.”This article was corrected online.

AB - Error in the Text: In the Original Investigation titled “A Budget Impact Analysis of Gene Therapy for Sickle Cell Disease: The Medicaid Perspective,” which published online March 22, 2021,1 there was an error in the Introduction section. The third sentence in the fourth paragraph of that section should read: “Agene therapy using the same lentiviral vector received conditional approval from the European Medicines Agency in 2019for the treatment of transfusion-dependent ß-thalassemia.”This article was corrected online.

UR - http://www.scopus.com/inward/record.url?scp=85107479668&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85107479668&partnerID=8YFLogxK

U2 - 10.1001/jamapediatrics.2021.1438

DO - 10.1001/jamapediatrics.2021.1438

M3 - Comment/debate

AN - SCOPUS:85107479668

SN - 2168-6203

VL - 175

SP - 647

JO - JAMA Pediatrics

JF - JAMA Pediatrics

IS - 6

ER -

Erratum: A budget impact analysis of gene therapy for sickle cell disease: The Medicaid perspective (JAMA Pediatr. (2021) DOI: 10.1001/jamapediatrics.2020.7140)

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this